QIAGEN's growth pillars together grew 4% constant exchange rate (CER) in Q1 2026, with sample technologies delivering 9% CER growth driven by demand for automated consumables and instrument placements. The company updated its full-year 2026 outlook to 1-2% CER sales growth from the previously guided 5%, citing headwinds from reduced QuantiFERON immigration testing demand and sustained caution among U.S. Life Sciences customers.
Cyborg Score Rationale
QIAGEN achieved adjusted diluted EPS guidance in Q1 2026 at $0.54 CER, demonstrating profitability execution despite sales headwinds. However, the significant downward revision of full-year guidance and softening customer demand in core Life Sciences markets create near-term uncertainty, though diversified growth pillars and innovation in AI-enabled platforms provide medium-term upside.
Top Insights
Lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other portfolio areas in Q1 2026
Sample technologies segment delivered 9% CER growth, with 3% growth ex-Parse acquisition, supported by automated consumables and instrument placements
QIAGEN introduced the QIAGEN Discovery Platform at the April 2026 AACR meeting as an AI-grounding solution for drug discovery that integrates biological knowledge, omics data and advanced analytics for oncology research
QuantiFERON sales declined 5% CER in Q1 2026 mainly due to significant decline in immigration testing demand in the United States and Middle East
Named Competitors
Illumina Sequencing — Leading next-generation sequencing and genomic analysis platforms
Diagnostics & Clinical Solutions — Molecular and clinical diagnostics consumables and instruments
Molecular Diagnostics — Broad diagnostics and point-of-care molecular testing solutions
Syndromic Testing — Rapid microbial identification and antimicrobial susceptibility testing
Recent Developments
(April 2026) Introduced QIAGEN Discovery Platform AI-grounding solution for drug discovery with integrated omics and analytics capabilities at AACR Annual Meeting
(April 2026) Reported Q1 2026 net sales of $492 million, up 2% reported basis but down 1% CER; lowered full-year 2026 guidance to 1-2% CER growth from 5%
(April 2026) Launched CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel for syndromic bloodstream infection testing
(February 2026) Reported 2025 net sales of $2.09B and achieved adjusted EPS of $2.38 ($2.40 CER), above guidance
Open the full interactive QIAGEN N.V. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.